Pacific Biosciences of California, Inc. (PACB) vs QuidelOrtho Corporation (QDEL)

A side-by-side comparison of Pacific Biosciences of California, Inc. and QuidelOrtho Corporation across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — PACB vs QDEL

growth of $100 · dividends reinvested · last 10y
PACB -68.1% (-10.8%/yr)QDEL -43.9% (-5.6%/yr)QDEL compounded faster over this window
05001kStart $10020182020202220242026$32$56
PACB QDEL

PACB vs QDEL: by the numbers

  • •QDEL is the larger company ($846M vs $835M market cap).
  • •Both run net losses; QDEL's is the smaller (-39.20% vs -82.49% net margin).
  • •PACB grew revenue faster over the past five years (8.52% vs 7.14% CAGR).

Metrics side by side

Valuation

MetricPACBQDEL
Forward P/EN/A16.05
P/S ratio5.240.32
P/B ratioN/A0.48

Profitability

MetricPACBQDEL
Gross margin35.97%44.60%
Operating margin-348.46%-30.67%
Net margin-82.49%-39.20%
ROEN/A-59.07%
ROIC-23.80%-16.05%

Growth (annualized)

MetricPACBQDEL
Revenue CAGR (5Y)8.52%7.14%
Total return CAGR (5Y)-35.20%-38.12%

Frequently asked

Which has grown faster, PACB or QDEL?
Over the past five years, PACB grew revenue faster — PACB at a 8.52% CAGR versus QDEL at 7.14%.
How have PACB and QDEL total returns compared?
Over the past 10 years, PACB delivered -10.80% and QDEL delivered -5.68% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.